151 related articles for article (PubMed ID: 37165281)
21. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract][Full Text] [Related]
22. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn E; Saadati M; Fenaux P; Gobbi M; Roboz GJ; Bullinger L; Lutsik P; Riedel A; Plass C; Jahn N; Walter C; Holzmann K; Hao Y; Naim S; Schreck N; Krzykalla J; Benner A; Keer HN; Azab M; Döhner K; Döhner H
Leukemia; 2023 Nov; 37(11):2187-2196. PubMed ID: 37591941
[TBL] [Abstract][Full Text] [Related]
24. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
25. Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.
Shin SY; Lee ST; Kim HJ; Cho EH; Kim JW; Park S; Jung CW; Kim SH
Oncotarget; 2016 Aug; 7(34):54825-54837. PubMed ID: 27359055
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
27. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.
Wang B; Hua X; Zhang J; Gu W; Li H
Cancer Med; 2023 Apr; 12(8):9420-9433. PubMed ID: 36808479
[TBL] [Abstract][Full Text] [Related]
28. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Sargas C; Ayala R; Larráyoz MJ; Chillón MC; Rodriguez-Arboli E; Bilbao C; Prados de la Torre E; Martínez-Cuadrón D; Rodríguez-Veiga R; Boluda B; Gil C; Bernal T; Bergua J; Algarra L; Tormo M; Martínez-Sánchez P; Soria E; Serrano J; Alonso-Dominguez JM; García R; Amigo ML; Herrera-Puente P; Sayas MJ; Lavilla-Rubira E; Martínez-López J; Calasanz MJ; García-Sanz R; Pérez-Simón JA; Gómez Casares MT; Sánchez-García J; Barragán E; Montesinos P;
Blood Cancer J; 2023 May; 13(1):77. PubMed ID: 37173322
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
31. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N; Jahn E; Saadati M; Bullinger L; Larson RA; Ottone T; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Ehninger G; Heuser M; Ganser A; Pallaud C; Gathmann I; Krzykalla J; Benner A; Bloomfield CD; Thiede C; Stone RM; Döhner H; Döhner K
Leukemia; 2022 Sep; 36(9):2218-2227. PubMed ID: 35922444
[TBL] [Abstract][Full Text] [Related]
32. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.
Bullinger L; Döhner K; Döhner H
J Clin Oncol; 2017 Mar; 35(9):934-946. PubMed ID: 28297624
[TBL] [Abstract][Full Text] [Related]
33. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
de Noronha TR; Mitne-Neto M; Chauffaille ML
J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
[TBL] [Abstract][Full Text] [Related]
34. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetically Normal Acute Myeloid Leukaemia at a Single Centre in South Africa.
Jenkins N; Blanshard LA; Stone M; Verburgh E; Oosthuizen J; Shires K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):397-406. PubMed ID: 37363984
[TBL] [Abstract][Full Text] [Related]
36. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
[TBL] [Abstract][Full Text] [Related]
37. An NGS based MRD evaluation from acute myeloid leukemia patients.
Chen B; Wang L; Wang Z; Zhang H; Chen L; Zhang L; Li J; Yan X; Zhao M; Lin Y; Ru K
Int J Lab Hematol; 2023 Jun; 45(3):353-359. PubMed ID: 36751002
[TBL] [Abstract][Full Text] [Related]
38. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
39. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Döhner K; Thiede C; Jahn N; Panina E; Gambietz A; Larson RA; Prior TW; Marcucci G; Jones D; Krauter J; Heuser M; Voso MT; Ottone T; Nomdedeu JF; Mandrekar SJ; Klisovic RB; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Benner A; Pallaud C; Stone RM; Döhner H; Bloomfield CD
Blood; 2020 Jan; 135(5):371-380. PubMed ID: 31826241
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of low allelic ratio
Sakaguchi M; Yamaguchi H; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Gomi S; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Nakajima N; Marumo A; Omori I; Fujiwara Y; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
Blood Adv; 2018 Oct; 2(20):2744-2754. PubMed ID: 30341082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
